[ad_1]
Germany’s Corona vaccine brings a breath of fresh air to the healthcare world amid a wave of virus that is increasingly spreading across the country.
Not a few of the people who are nervous about the virus. They cannot perform various daily activities.
Not only the positive victims who experienced the effects of Covid-19, even those who were healthy also felt all the effects.
German crown vaccine on trial
German Mainz-based company BioNtech said it was ready to distribute millions of Corona vaccines later this year.
BioNtech has collaborated with the United States pharmacy, which is actually the largest pharmacy.
If the vaccine is successful in testing and passes international standards, these two big companies have given the ability to produce it by 2021.
It is estimated that by the end of this year it can supply German Corona vaccines in quantities. It depends on the level of technical success in the development program and has been approved by the regulatory authority.
In the first period, volunteers will receive a potential dose of BNT162 vaccine in phase 1/2 clinical trials in Germany.
Trials will be conducted with 200 volunteers to discover how this vaccine works. These volunteers are between 18 and 52 years old and are susceptible to the Corona virus.
The German Corona vaccine is tested on each volunteer. Where volunteers will receive injections ranging from 1 microgram to 100 micrograms.
This is done to find out how much dose to cure Corona patients. BioNTech said it would investigate the safety and immunization of this vaccine.
While rehearsals will be held in the United States next week, the fastest. The vaccine can be used in an emergency at least starting next fall.
The two companies began developing trials ranging from Europe and the United States at various research locations.
Gilead Pharmaceutical Company
In the United States, the pharmaceutical company Gilead has obtained positive data about its medicine, which has been shown to help the recovery process for Corona patients.
This also increases its effectiveness, which is used in the early stages of patients experiencing symptoms of the Corona virus.
Research will now continue to ensure that Remdesiver can be formalized as a drug for the treatment of Corona virus (Covid-19).
Vaccine testing at Oxford
In addition to Germany’s Corona vaccine trials, there are still other companies that also have the potential to develop Corona vaccines with success rates as well. From scientists at Oxford University, the United Kingdom has also started research on human vaccine trials.
If this trial is successful, by the end of September you will also be able to distribute Corona vaccines in large quantities. There are currently 86 teams worldwide that have worked together to develop and produce the Corona virus vaccine.
First vaccines developed in China
The Beijing-based China investigation is considered quite advanced. Which is an affiliate of the country-owned China National Pharmaceutical Group.
Last March, China gave a green signal to conduct clinical trials on vaccine candidates that had been developed at the Chinese Military Medical Academy, where it collaborated with a Hong Kong-registered biotech company.
Research into the German Corona vaccine will complete all trials worldwide. With several studies, it is expected to provide good results.
If a vaccine that has been tested in humans and provides satisfactory results or, in other words, is capable of curing Corona patients, of course a large-scale acquisition will be made.
Many patients who have contracted the Corona virus really hope that there is good news. It is hoped that not only vaccines in Germany can handle the virus, but also vaccines that have been tested in several other studies.
Millions of people around the world expect these vaccines to cure the Corona virus. It is undeniable that Corona is not just the positive victim who feels the impact.
However, everyone feels its effects, from losing jobs to starving. The German Corona vaccine is expected to free the world from the death threat of Covid-19. (R10 / HR-Online)
